Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies

• Published in: Scientific reports Vol. 5; no. 1; p. 13410
• Main Authors: Zhou, Quan, Luo, Mei-Ling, Li, Hui, Li, Min, Zhou, Jian-Guo
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 25.08.2015
• Subjects: Adult; Age Distribution; Aged; Caffeine; Caffeine - administration & dosage; Cancer; Causality; Coffee; Cohort analysis; Cohort Studies; Drinking Behavior; Endometrial cancer; Endometrial Neoplasms - epidemiology; Endometrium; Female; Health risk assessment; Hormone Replacement Therapy - statistics & numerical data; Humans; Incidence; Meta-analysis; Middle Aged; Prospective Studies; Risk Assessment
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep13410

This is a dose-response (DR) meta-analysis to evaluate the association of coffee consumption on endometrial cancer (EC) risk. A total 1,534,039 participants from 13 published articles were added in this meta-analysis. The RR of total coffee consumption and EC were 0.80 (95% CI: 0.74-0.86). A stronger association between coffee intake and EC incidence was found in patients who were never treated with hormones, 0.60 (95% CI: 0.50-0.72), and subjects with a BMI ≥25 kg/m(2), 0.57 (95% CI: 0.46-0.71). The overall RRs for caffeinated and decaffeinated coffee were 0.66 (95% CI: 0.52-0.84) and 0.77 (95% CI: 0.63-0.94), respectively. A linear DR relationship was seen in coffee, caffeinated coffee, decaffeinated coffee and caffeine intake. The EC risk decreased by 5% for every 1 cup per day of coffee intake, 7% for every 1 cup per day of caffeinated coffee intake, 4% for every 1 cup per day of decaffeinated intake of coffee, and 4% for every 100 mg of caffeine intake per day. In conclusion, coffee and intake of caffeine might significantly reduce the incidence of EC, and these effects may be modified by BMI and history of hormone therapy.